Telomir-1 Selectively Kills Aggressive Triple-Negative Breast Cancer Cells by Disrupting Iron and Energy Pathways

Telomir's experimental drug, Telomir-1, kills aggressive TNBC cells. It targets their high dependence on iron and energy, exploiting a key weakness.